As of 2026-03-19, the Fair Value of Editas Medicine Inc (EDIT) is -8.20 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 2.35 USD, the upside of Editas Medicine Inc is -448.86%.
With the market price of 2.35 USD and our fair value calculation, Editas Medicine Inc (EDIT) is not a good investment. Investing in EDIT stocks now will result in a potential loss of 448.86%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | 5Y Avg | |
| Net income | -192.50 | -220.43 | -153.22 | -237.09 | -160.06 | -192.66 |
| YoY growth | -65.98% | -14.51% | 30.49% | -54.74% | 32.49% | -14.45% |
| Market Cap (mil) | 229.41 |
| P/E | |
| Forward P/E |
| EPS | -1.64 |
| Avg earnings growth rate | -14.45% |
| TTM earnings | -160.06 |